Capital Fund Management S.A. purchased a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Rating) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 34,926 shares of the biotechnology company's stock, valued at approximately $942,000. Capital Fund Management S.A. owned about 0.13% of Arcturus Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. KRS Capital Management LLC acquired a new stake in Arcturus Therapeutics during the 4th quarter worth approximately $51,000. Byrne Asset Management LLC bought a new stake in shares of Arcturus Therapeutics in the fourth quarter worth $114,000. Daiwa Securities Group Inc. grew its stake in shares of Arcturus Therapeutics by 44.0% in the first quarter. Daiwa Securities Group Inc. now owns 3,503 shares of the biotechnology company's stock worth $94,000 after purchasing an additional 1,071 shares during the last quarter. Ensign Peak Advisors Inc bought a new position in Arcturus Therapeutics during the 4th quarter worth $261,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in Arcturus Therapeutics by 9.0% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 8,298 shares of the biotechnology company's stock worth $224,000 after buying an additional 687 shares during the period. Institutional investors and hedge funds own 83.55% of the company's stock.

Arcturus Therapeutics Stock Down 7.2 %

ARCT stock opened at $14.32 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.05 and a current ratio of 3.05. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $11.70 and a fifty-two week high of $58.09. The stock's 50 day simple moving average is $17.45 and its 200 day simple moving average is $19.90. The company has a market cap of $380.57 million, a P/E ratio of -2.28 and a beta of 2.70.

Analyst Ratings Changes

ARCT has been the subject of several recent research reports. Robert W. Baird raised Arcturus Therapeutics from an "underperform" rating to a "neutral" rating and decreased their price target for the company from $21.00 to $18.00 in a research note on Wednesday, May 11th. Raymond James downgraded shares of Arcturus Therapeutics from a "market perform" rating to an "underperform" rating in a research report on Wednesday, August 10th. The Goldman Sachs Group lowered their target price on shares of Arcturus Therapeutics from $14.00 to $8.00 and set a "sell" rating for the company in a research note on Tuesday, May 24th. Wells Fargo & Company cut their price target on shares of Arcturus Therapeutics from $105.00 to $98.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 10th. Finally, Brookline Capital Management reissued a "buy" rating on shares of Arcturus Therapeutics in a research report on Wednesday, August 10th. Four investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $38.75.

Arcturus Therapeutics Profile

(Get Rating)

Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.

See Also

• Get a free copy of the StockNews.com research report on Arcturus Therapeutics (ARCT)
• Could Snap Stock Rebound As Management Restructures?
• MarketBeat: Week in Review 8/29 – 9/2
• Hormel Looks Cheap At These Levels
• Lululemon Set To Soar Into September
• Could Nike Stock be Oversold, but Still Overvalued?

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.